{"id":20547,"date":"2023-10-17T10:07:57","date_gmt":"2023-10-17T08:07:57","guid":{"rendered":"https:\/\/ggba.swiss\/mimix-biotherapeutics-breakthrough-tissue-regeneration-treatment-receives-strategic-investment\/"},"modified":"2023-10-17T10:11:35","modified_gmt":"2023-10-17T08:11:35","slug":"investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/","title":{"rendered":"Nouveaux fonds pour le traitement de r\u00e9g\u00e9n\u00e9ration tissulaire de Mimix Biotherapeutics"},"content":{"rendered":"\n<p>Situ\u00e9e \u00e0 Bienne (canton de Berne), <a href=\"https:\/\/www.mimixbio.com\/\">Mimix Biotherapeutics<\/a> a investi plus d&rsquo;une d\u00e9cennie dans la recherche et le d\u00e9veloppement. Son produit phare, FastSkin, est r\u00e9v\u00e9lateur du potentiel futur de la m\u00e9decine personnalis\u00e9e. Bien que FastSkin reste une priorit\u00e9, les int\u00e9r\u00eats de l&rsquo;entreprise couvrent un large \u00e9ventail de domaines, notamment la m\u00e9decine r\u00e9g\u00e9n\u00e9rative, le d\u00e9veloppement de m\u00e9dicaments et l&rsquo;agriculture cellulaire.<\/p>\n\n\n\n<p>Au c\u0153ur des innovations de Mimix se trouve la technologie de morphogen\u00e8se induite par le son (<a href=\"https:\/\/www.mimixbio.com\/technology\">SIM<\/a>). Ce processus utilise des ondes acoustiques pour structurer des mat\u00e9riaux biologiques, tels que des cellules ou des tissus, en constructions tridimensionnelles pr\u00e9cises. Emulant les strat\u00e9gies de conception complexes de la nature, il offre une nouvelle approche des applications biom\u00e9dicales.<\/p>\n\n\n\n<p>Le tour de table a \u00e9t\u00e9 r\u00e9alis\u00e9 gr\u00e2ce aux contributions de l&rsquo;investisseur historique <a href=\"https:\/\/www.heraeus-group.com\/en\/\">Heraeus Group<\/a> et du nouveau venu Asia Jetway Pte. Ce dernier, dont le si\u00e8ge est \u00e0 Singapour, est connu pour son vaste portefeuille de solutions de soins de sant\u00e9 dans toute l&rsquo;Asie du Sud-Est, comprenant des soci\u00e9t\u00e9s affili\u00e9es telles que LandMover, Shanghai Keyman, et d&rsquo;autres.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Innover dans le domaine du traitement des plaies chroniques<\/h4>\n\n\n\n<p>La vision commune de ces investisseurs s&rsquo;aligne sur l&rsquo;objectif de Mimix, qui est de faire progresser les m\u00e9thodes de traitement des plaies. FastSkin est consid\u00e9r\u00e9 comme un traitement susceptible d&rsquo;optimiser les soins aux patients et de r\u00e9duire les d\u00e9penses de sant\u00e9.<\/p>\n\n\n\n<p>Marc Thurner, CEO de Mimix, a d\u00e9clar\u00e9 : \u00ab&nbsp;Nous sommes ravis de b\u00e9n\u00e9ficier du soutien du groupe Heraeus et d&rsquo;Asia Jetway, alors que nous travaillons \u00e0 la mise sur le march\u00e9 de notre traitement innovant des plaies. Leur expertise et leurs ressources seront inestimables pour acc\u00e9l\u00e9rer les plans de mise sur le march\u00e9 et d&rsquo;internationalisation.&nbsp;\u00bb<\/p>\n\n\n\n<p>Avec la conclusion de ce financement, Mimix se rapproche de la r\u00e9alisation de sa mission d&rsquo;innovation dans le domaine du traitement des plaies chroniques. Conform\u00e9ment \u00e0 sa feuille de route, Mimix recherche activement des collaborations et des partenariats avec l&rsquo;industrie et le monde universitaire, dans le but d&rsquo;exploiter davantage ses technologies exclusives dans un contexte biom\u00e9dical plus large.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La soci\u00e9t\u00e9 biennoise Mimix Biotherapeutics a annonc\u00e9 la cl\u00f4ture d&rsquo;un important tour d&rsquo;investissement, auquel ont particip\u00e9 des investisseurs europ\u00e9ens et asiatiques. Cet apport de capitaux est destin\u00e9 au d\u00e9veloppement clinique de FastSkin, une nouvelle m\u00e9thode de traitement des plaies chroniques et aigu\u00ebs.<\/p>\n","protected":false},"author":6,"featured_media":20543,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1169,1148,1163,1141],"class_list":["post-20547","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-biotech-fr-2","tag-financing-fr-2","tag-medtech-fr-2","tag-personalized-medicine-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Financement pour le traitement de r\u00e9g\u00e9n\u00e9ration tissulaire de Mimix<\/title>\n<meta name=\"description\" content=\"Mimix a annonc\u00e9 la cl\u00f4ture d&#039;un important tour d&#039;investissement avec la participation d&#039;investisseurs europ\u00e9ens et asiatiques.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Financement pour le traitement de r\u00e9g\u00e9n\u00e9ration tissulaire de Mimix\" \/>\n<meta property=\"og:description\" content=\"Mimix a annonc\u00e9 la cl\u00f4ture d&#039;un important tour d&#039;investissement avec la participation d&#039;investisseurs europ\u00e9ens et asiatiques.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-17T08:07:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-17T08:11:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Nouveaux fonds pour le traitement de r\u00e9g\u00e9n\u00e9ration tissulaire de Mimix Biotherapeutics\",\"datePublished\":\"2023-10-17T08:07:57+00:00\",\"dateModified\":\"2023-10-17T08:11:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/\"},\"wordCount\":400,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg\",\"keywords\":[\"Biotech\",\"Financing\",\"Medtech\",\"Personalized Medicine\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/\",\"name\":\"Financement pour le traitement de r\u00e9g\u00e9n\u00e9ration tissulaire de Mimix\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg\",\"datePublished\":\"2023-10-17T08:07:57+00:00\",\"dateModified\":\"2023-10-17T08:11:35+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"Mimix a annonc\u00e9 la cl\u00f4ture d'un important tour d'investissement avec la participation d'investisseurs europ\u00e9ens et asiatiques.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"L'objectif de Mimix, tel que d\u00e9crit dans sa vision strat\u00e9gique, est d'introduire ce produit de traitement des plaies sur le march\u00e9 am\u00e9ricain d'ici le second semestre 2024. | \u00a9 Mimix Biotherapeutics\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nouveaux fonds pour le traitement de r\u00e9g\u00e9n\u00e9ration tissulaire de Mimix Biotherapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Financement pour le traitement de r\u00e9g\u00e9n\u00e9ration tissulaire de Mimix","description":"Mimix a annonc\u00e9 la cl\u00f4ture d'un important tour d'investissement avec la participation d'investisseurs europ\u00e9ens et asiatiques.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/","og_locale":"fr_FR","og_type":"article","og_title":"Financement pour le traitement de r\u00e9g\u00e9n\u00e9ration tissulaire de Mimix","og_description":"Mimix a annonc\u00e9 la cl\u00f4ture d'un important tour d'investissement avec la participation d'investisseurs europ\u00e9ens et asiatiques.","og_url":"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-10-17T08:07:57+00:00","article_modified_time":"2023-10-17T08:11:35+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Nouveaux fonds pour le traitement de r\u00e9g\u00e9n\u00e9ration tissulaire de Mimix Biotherapeutics","datePublished":"2023-10-17T08:07:57+00:00","dateModified":"2023-10-17T08:11:35+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/"},"wordCount":400,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg","keywords":["Biotech","Financing","Medtech","Personalized Medicine"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/","url":"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/","name":"Financement pour le traitement de r\u00e9g\u00e9n\u00e9ration tissulaire de Mimix","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg","datePublished":"2023-10-17T08:07:57+00:00","dateModified":"2023-10-17T08:11:35+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"Mimix a annonc\u00e9 la cl\u00f4ture d'un important tour d'investissement avec la participation d'investisseurs europ\u00e9ens et asiatiques.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Mimix-Fast-Skin-1180x811-1.jpg","width":1180,"height":811,"caption":"L'objectif de Mimix, tel que d\u00e9crit dans sa vision strat\u00e9gique, est d'introduire ce produit de traitement des plaies sur le march\u00e9 am\u00e9ricain d'ici le second semestre 2024. | \u00a9 Mimix Biotherapeutics"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/investissement-strategique-pour-le-traitement-revolutionnaire-de-regeneration-tissulaire-de-mimix-biotherapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Nouveaux fonds pour le traitement de r\u00e9g\u00e9n\u00e9ration tissulaire de Mimix Biotherapeutics"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20547","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=20547"}],"version-history":[{"count":2,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20547\/revisions"}],"predecessor-version":[{"id":20551,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20547\/revisions\/20551"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/20543"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=20547"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=20547"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=20547"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}